GOLM1 and metabolic dysfunction-associated steatotic liver disease: Strikingly, it discovered that metformin, the multi-target drug used for lowering the blood glucose and some other diseases (60, 61), can inhibit NAFLD progression by suppressing the Rab-GAP activity of GP73, suggesting that GP73 serves as a potential drug target in combating NAFLD.